Life Sciences Tools and Services

Waters

Bank of America Raises Waters Target Price to $400, Maintains Neutral Rating

Wolfe Research Maintains Buy Rating on Waters, Raises Target Price to $425

Waters Unveils Xevo MRT P10 MS to Accelerate Multi-Omics Research

Waters Launches Cyclic Ion Mobility Spectrometry P20 Mass Spectrometer: New Benchmark for Structural and Spatial Omics

JPMorgan Raises Water's Target Price to $345

Waters released FY2026 Q1 earnings on May 5 Pre-Market EST, actual revenue USD 1.267 B (forecast USD 1.203 B), actual EPS USD -0.8765 (forecast USD 2.0225)

Waters Raises Full-Year Profit Forecast

Waters Corporation Q1 2026 Earnings Report: Revenue Exceeds Expectations, EPS Misses Estimates

Waters Corporation to Release Q1 Earnings on Tuesday

Waters to Release FY2026 Q1 Earnings on May 5, Pre-Market EST; Forecast Revenue USD 1.203 B, EPS USD 2.08

Waters Launches omniDAWN Multi-Angle Light Scattering Photometer

KBC Group NV increased its stake in Waters Corp in Q4

Waters Reports Q1 2026 Earnings

Waters Introduces Waters™ omniDAWN Multi-Angle Light Scattering System

Waters Launches New MALS Detector

Waters Gains FDA Approval for Cervical Cancer Screening Tool

Deutsche Bank downgrades Waters target price to $330

Waters Corp's Director Jiang Wei Purchased 500 Shares of Common Stock

Waters Corporation Issues $3.5 Billion Senior Notes to Refinance Debt

Alliancebernstein Significantly Cut Holdings in Waters

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

Watsco, Inc. (WSO.US) Q1 2025 Earnings Conference Call

Waters Corp. (WAT) shares rose 2.15% to $371.15 on Tuesday, ending a three-day losing streak. However, the stock underperformed relative to competitors like Thermo Fisher Scientific and Danaher, which posted larger gains. Trading volume matched its 50-day average. Despite the daily rise, WAT remains 10.38% below its 52-week high of $414.15 reached in late November.

MarketWatch Automated

Dow Jones Industrial Average

S&P 500

Thermo Fisher Scentific

Danaher

GE Aerospace

Waters Corp. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Waters Corporation reported a strong Q1 2026, with adjusted EPS up 20% and revenue growth driven by the BD Biosciences acquisition. The company secured FDA 510(k) clearance for the BD BACTEC FXI Culture System and launched new mass spectrometry platforms. These developments aim to validate the integration strategy and support recurring revenue growth, though execution risks remain. Analysts project $7.5 billion in revenue by 2029.

Simplywall

Becton Dickinson and

What Waters (WAT)'s Diagnostics Wins and Q1 Beat Mean For Shareholders

Waters Corp. (WAT) shares fell 2.95% to $365.36 on Friday, underperforming competitors like Thermo Fisher Scientific and Danaher during a broad market decline. The S&P 500 dropped 2.64%, and the Dow Jones fell 1.35%. This marked Waters' second consecutive day of losses, with the stock closing 11.78% below its 52-week high. Trading volume was significantly lower than the 50-day average.

Factset Research

Waters Corp. Stock Underperforms Friday When Compared To Competitors

Kohl's Corp. (KSS) shares rose 6.38% to $15.85, outperforming competitors Amazon, Walmart, and Target on a favorable trading day. This marks the second consecutive gain for Kohl's, though it remains 37.15% below its 52-week high of $25.22. Trading volume reached 6.7 million, exceeding the 50-day average.

Kohls

Amazon

Walmart

Target

Kohl's Corp. Stock Outperforms Competitors On Strong Trading Day

Waters Corporation (WAT) announced that the BD BACTEC FXI Culture System has received FDA 510(k) clearance. This next-generation, fully automated blood culture system aims to enhance the speed, consistency, and accuracy of bloodstream infection diagnostics. It automates vial handling and detection, offering a 50% higher capacity than competitors and reducing mean time to detection by approximately three hours compared to previous models.

rttnews

Waters Corp. Gets FDA Clearance For BD BACTEC FXI Culture System

Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics | WAT Stock News

StockTitan

Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics | WAT Stock News

Waters Corp. (WAT) shares fell 1.65% to $371.93, marking its second consecutive day of losses and closing 10.19% below its 52-week high. Despite the decline, WAT outperformed competitors Thermo Fisher Scientific, Danaher, and GE Aerospace, which all saw larger percentage drops. Trading volume remained significantly below the 50-day average.

Waters Corp. Stock Outperforms Competitors Despite Losses On The Day

STLD

Steel Dynamics Inc. (STLD) has surpassed Waters Corp. (WAT) in market capitalization, moving up to the #276 spot in the S&P 500 rankings. STLD's market cap stands at $37.72 billion compared to WAT's $37.13 billion. This shift highlights the importance of market cap for comparing company values and determining eligibility for specific investment funds.

nasdaq

Steel Dynamics

Nasdaq

Steel Dynamics Moves Up In Market Cap Rank, Passing Waters

Bank of America raised its price target for Waters (NYSE:WAT) from $370 to $400, maintaining a 'neutral' rating. This follows other analyst actions, including Morgan Stanley's cut and Wells Fargo's increase. The stock recently reported strong Q1 earnings, beating estimates on both EPS and revenue, with YoY revenue up 91.4%. Institutional investors like Vanguard and Fundsmith increased their stakes in the third quarter.

Market Beat

Bank of America

Agilent Tech

Morgan Stanley

Wells Fargo

Illumina

Janus Henderson

Invesco

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Waters (NYSE:WAT) Price Target Raised to $400.00

Wolfe Research analyst Michael Polark maintained a Buy rating on Waters (WAT) with a $425 price target. This contrasts with the current moderate buy consensus and average price target of $383.80. Polark, who covers healthcare stocks including Boston Scientific and Abbott Laboratories, has a 6.4% average return and 50% success rate on recommendations.

Tip Ranks

Boston Scientific

Abbott Laboratories

Waters (WAT) Gets a Buy from Wolfe Research

Waters(WAT.US)

Waters Corp. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

What Waters (WAT)'s Diagnostics Wins and Q1 Beat Mean For Shareholders

Waters Corp. Stock Underperforms Friday When Compared To Competitors

Kohl's Corp. Stock Outperforms Competitors On Strong Trading Day

Waters Corp. Gets FDA Clearance For BD BACTEC FXI Culture System

Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics | WAT Stock News

Waters Corp. Stock Outperforms Competitors Despite Losses On The Day

Steel Dynamics Moves Up In Market Cap Rank, Passing Waters

Waters (NYSE:WAT) Price Target Raised to $400.00

Waters (WAT) Gets a Buy from Wolfe Research